Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + IP/IV Paclitaxel + S-1 in Gastric Cancer with Peritoneal Metastasis
NCT05204173Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in gastric cancer (GC), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05204173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05204173.